investingg.ininvestingg.inAI-powered equity research assistant
← All curated stocks

AbbVie Inc. (ABBV)

Pharmaceutical Preparations · Pharmaceutical Preparations · NYSE

$259.93

-0.63%

Investru Score

50.9 / 100

Neutral

Why is ABBV moving?

ABBV is down 0.63% today, a pullback within its broader uptrend.

Recent coverage: AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Business overview

  • The company operates in the pharmaceutical preparations sector.
  • The asset type is equity.

These structural classifications place the company within the pharmaceutical preparations industry, though broader operational details are constrained by the available dataset.

Bull case

The bull case relies on sustained revenue growth of 8.6% alongside strong free cash flow generation at 29.1% margin and positive technical momentum showing the stock trading 12.4% above its 200-day average. If these operational strengths persist alongside an attractive forward P/E of 16.93, the company could see expanded valuation multiples.

Bear case

The bear case centers on deteriorating bottom-line metrics, including a negative return on equity of -129.2% and contracting EPS growth of -1.3%. If liquidity pressures intensify given a current ratio of 0.67 and net debt-to-EBITDA of 3.74, financial flexibility could become severely constrained.

ABBV’s Investru Score changed -3.6 points recently. Want to know exactly what changed and why? That’s a Pro feature →

Score breakdown

Financial Quality
60
Growth
37
Profitability
41
Balance Sheet
40
Valuation
67
Momentum
62

Score history

-3.6 over the last 32 days, driven mainly by momentum (-36).

Financial quality

  • The return on invested capital stands at 6.9%.
  • The return on equity is -129.2%.
  • The free cash flow margin is 29.1%.
  • The earnings quality score is 4.5.

Together, these figures indicate strong cash generation capabilities alongside notable structural distortions in equity returns and a moderate return on invested capital.

ROIC
6.9%
ROE
-129.2%
FCF Margin
29.1%
Free Cash Flow (TTM)
$17.8B
Earnings Quality (OCF ÷ Net Income)
4.5x

Valuation

  • The forward P/E ratio is 16.93.
  • The EV-to-EBITDA ratio is 3.3.
  • The trailing P/E ratio is not available.
  • The trailing PEG is not available.
  • The forward PEG is not available.
  • The median PEG is not available.
  • The price-to-sales ratio is 0.
  • The free cash flow yield is not available.

These valuation indicators suggest an accessible earnings multiple and a low enterprise value relative to earnings, though several missing valuation metrics introduce valuation uncertainty.

P/E (TTM)
Data unavailable
Forward P/E
16.9x
PEG (P/E ÷ EPS Growth)
Data unavailable
Company Median PEG
Data unavailable
Price / Sales
0.0x
EV / EBITDA
3.3x
FCF Yield
Data unavailable

Key risks

  • The current ratio of 0.67 indicates that short-term obligations exceed liquid assets, raising short-term liquidity risks.(Probability: High · Impact: High)
  • A negative margin trend of -7.2% suggests ongoing pressure on profitability margins.(Probability: High · Impact: Medium)
  • A net debt-to-EBITDA ratio of 3.74 signifies elevated leverage relative to core earnings.(Probability: Medium · Impact: High)

Latest earnings

Q2 FY26 EPS
$2.03
Estimate
Data unavailable
Surprise
Data unavailable
  • The year-over-year EPS growth is -1.3%.
  • The earnings quality score is 4.5.

These metrics suggest that earnings have contracted slightly year-over-year while maintaining a moderate quality assessment.

SEC filings

Event filings (8-K) aren't covered by this page's data source yet — only 10-K/10-Q are shown above.

Market cap $0 · 52-week range $190.75–$269.39 · market data as of Oct 1, 2026, 4:04 PM ET · latest SEC filing: 2026-08-03

Related stocks

ABT

ABBOTT LABORATORIES

51/100 · Neutral

BMY

BRISTOL MYERS SQUIBB CO

56/100 · Good

JNJ

JOHNSON & JOHNSON

65/100 · Good

LLY

ELI LILLY & Co

62/100 · Good

MRK

Merck & Co., Inc.

56/100 · Good

PFE

PFIZER INC

44/100 · Weak

Get the full interactive report

Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.

Analyze ABBV with Investru AI

Not investment advice. Investru AI summarizes public data and AI-generated analysis for informational purposes only.